Expert Interview
Discussing Summit's recent Phase 3 HARMONi-2 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1- positive Advanced NSCLC
Ticker(s): SMMTInstitution: Duke
- Professor of Medicine at Duke University and member of Thoracic Oncology at Duke Cancer Institute
- Treats 75 patients with PD-L1- positive Advanced NSCLC
- Research focus is clinical trials on non-small cell lung cancer and small cell lung cancer,
Roughly how many patients do you treat per year for PD-L1- positive Advanced NSCLC and what is your current standard of care for these patients?
Added By: sara_adminWhat are your take aways from the recent Phase 3 HARMONi-2 Study data?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of ivonescimab, what would it be and why?
Added By: sara_adminWhat are your thoughts on the HARMONi-2 trial results for ivonescimab compared to pembrolizumab, and do you think the bispecific mechanism offers any clinical advantage?
How do you interpret the progression-free survival (PFS) and objective response rate (ORR) results from the trial, and do you think they will translate into an overall survival benefit?
What is your view on the safety profile of ivonescimab, especially regarding the VEGF-related toxicities, and is there a difference in its effects on squamous versus non-squamous NSCLC?
Added By: catalin_adminDo you think ivonescimab could pose a significant threat to Keytruda, and how excited are you about its potential to change the treatment landscape for NSCLC?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
